- Home
- SGD vs HEPA Comparison
SGD vs HEPA Comparison
Compare SGD & HEPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGD
- HEPA
- Stock Information
- Founded
- SGD 2021
- HEPA 2013
- Country
- SGD United States
- HEPA United States
- Employees
- SGD N/A
- HEPA N/A
- Industry
- SGD
- HEPA Biotechnology: Pharmaceutical Preparations
- Sector
- SGD
- HEPA Health Care
- Exchange
- SGD Nasdaq
- HEPA Nasdaq
- Market Cap
- SGD 4.1M
- HEPA 4.1M
- IPO Year
- SGD N/A
- HEPA N/A
- Fundamental
- Price
- SGD $1.96
- HEPA $0.47
- Analyst Decision
- SGD
- HEPA
- Analyst Count
- SGD 0
- HEPA 0
- Target Price
- SGD N/A
- HEPA N/A
- AVG Volume (30 Days)
- SGD 615.6K
- HEPA 100.9K
- Earning Date
- SGD 01-01-0001
- HEPA 11-14-2024
- Dividend Yield
- SGD N/A
- HEPA N/A
- EPS Growth
- SGD N/A
- HEPA N/A
- EPS
- SGD N/A
- HEPA N/A
- Revenue
- SGD $173,188.00
- HEPA N/A
- Revenue This Year
- SGD N/A
- HEPA N/A
- Revenue Next Year
- SGD N/A
- HEPA N/A
- P/E Ratio
- SGD N/A
- HEPA N/A
- Revenue Growth
- SGD N/A
- HEPA N/A
- 52 Week Low
- SGD $1.45
- HEPA $0.43
- 52 Week High
- SGD $53.80
- HEPA $3.49
- Technical
- Relative Strength Index (RSI)
- SGD 38.33
- HEPA 42.44
- Support Level
- SGD $1.81
- HEPA $0.43
- Resistance Level
- SGD $2.74
- HEPA $0.53
- Average True Range (ATR)
- SGD 0.32
- HEPA 0.07
- MACD
- SGD -0.05
- HEPA -0.01
- Stochastic Oscillator
- SGD 12.30
- HEPA 13.36
About SGD Safe and Green Development Corporation
Safe & Green Development Corp is a real estate development company that focuses on the development of sites using purpose built, prefabricated modules built from both wood & steel, sourced from one of Safe & Green Holdings factories. The company's business model is flexible and it anticipates developing properties on its own and also through joint ventures in which it partner with third-party equity investors or other developers.
About HEPA Hepion Pharmaceuticals Inc.
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.